Crosstalk between COVID-19 and prostate cancer.
Prostate Cancer Prostatic Dis
; 23(4): 561-563, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-680650
ABSTRACT
A new coronavirus, named SARS-CoV-2, emerged in Wuhan city, China, in December 2019 causing atypical pneumonia and affecting multiple body organs. The rapidly increasing numbers of infected patients and deaths due to COVID-19 disease necessitated declaring it as a global pandemic. Efforts were combined since then to rapidly develop a treatment and/or a vaccine to combat the deadly virus. Drug repurposing approach has been pursued as a temporary management tactic to treat COVID-19 patients. However, reports about the efficacy of many of the used drugs had been controversial with a dire need to keep the ongoing efforts for rapid development of new treatments. Promising data came out pointing to a possible hidden liaison between prostate cancer (PCa) and COVID-19, where androgen-deprivation therapies (ADT) used in PCa had been shown to instigate a protective role against COVID-19. Delving into the possible mechanisms underlying the crosstalk between COVID-19 and PCa alludes a potential association between SARS-CoV-2 targets on host epithelial cells and PCa genetic aberrations and molecular signatures, including AR and TMPRSS2. The question remains Can PCa treatments serve as potential therapeutic options for COVID-19 patients?
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Prostatic Neoplasms
/
Coronavirus Infections
/
Betacoronavirus
/
Androgen Antagonists
Type of study:
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Prostate Cancer Prostatic Dis
Journal subject:
Endocrinology
/
Neoplasms
/
Urology
Year:
2020
Document Type:
Article
Affiliation country:
S41391-020-0262-y
Similar
MEDLINE
...
LILACS
LIS